The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
Key Highlights
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $437.0 billion in 2018.The Mexico was the fastest growing country, with a CAGR of 4.6% over the 2014-18 period.
- Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $392.8 billion in 2018. This was followed by Canada and Mexico, with a value of $23.5 and $20.7 billion, respectively.
- The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $484.7 billion in 2023, followed by Canada and Mexico with expected values of $26.4 and $24.6 billion, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
- Leading company profiles reveal details of key pharmaceuticals market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to buy
- What was the size of the NAFTA pharmaceuticals market by value in 2018?
- What will be the size of the NAFTA pharmaceuticals market in 2023?
- What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA pharmaceuticals market?
Companies mentioned
Table of Contents
Table of Contents
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA Pharmaceuticals
Industry Outlook
Pharmaceuticals ...
Table of Contents
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA Pharmaceuticals
Industry Outlook
Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading Companies
Appendix
Methodology
About MarketLine
List of Tables
List of Tables
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-23
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-18
Table 3: NAFTA countries ...
List of Tables
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-23
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-18
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2018-23
Table 4: Canada pharmaceuticals market value: $ billion, 2014-18
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2018
Table 6: Canada pharmaceuticals market share: % share, by value, 2018
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2018-23
Table 8: Canada size of population (million), 2014-18
Table 9: Canada gdp (constant 2005 prices, $ billion), 2014-18
Table 10: Canada gdp (current prices, $ billion), 2014-18
Table 11: Canada inflation, 2014-18
Table 12: Canada consumer price index (absolute), 2014-18
Table 13: Canada exchange rate, 2014-18
Table 14: Mexico pharmaceuticals market value: $ billion, 2014-18
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2018
Table 16: Mexico pharmaceuticals market share: % share, by value, 2018
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2018-23
Table 18: Mexico size of population (million), 2014-18
Table 19: Mexico gdp (constant 2005 prices, $ billion), 2014-18
Table 20: Mexico gdp (current prices, $ billion), 2014-18
Table 21: Mexico inflation, 2014-18
Table 22: Mexico consumer price index (absolute), 2014-18
Table 23: Mexico exchange rate, 2014-18
Table 24: United States pharmaceuticals market value: $ billion, 2014-18
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2018
Table 26: United States pharmaceuticals market share: % share, by value, 2018
Table 27: United States pharmaceuticals market value forecast: $ billion, 2018-23
Table 28: United States size of population (million), 2014-18
Table 29: United States gdp (constant 2005 prices, $ billion), 2014-18
Table 30: United States gdp (current prices, $ billion), 2014-18
Table 31: United States inflation, 2014-18
Table 32: United States consumer price index (absolute), 2014-18
Table 33: United States exchange rate, 2014-18
Table 34: Apotex, Inc.: key facts
Table 35: Johnson & Johnson: key facts
Table 36: Johnson & Johnson: key financials ($)
Table 37: Johnson & Johnson: key financial ratios
Table 38: Bayer AG: key facts
Table 39: Bayer AG: key financials ($)
Table 40: Bayer AG: key financials (€)
Table 41: Bayer AG: key financial ratios
Table 42: Novartis AG: key facts
Table 43: Novartis AG: key financials ($)
Table 44: Novartis AG: key financial ratios
Table 45: AstraZeneca PLC: key facts
Table 46: AstraZeneca PLC: key financials ($)
Table 47: AstraZeneca PLC: key financial ratios
Table 48: Merck & Co., Inc.: key facts
Table 49: Merck & Co., Inc.: key financials ($)
Table 50: Merck & Co., Inc.: key financial ratios
Table 51: Pfizer Inc: key facts
Table 52: Pfizer Inc: key financials ($)
Table 53: Pfizer Inc: key financial ratios
List of Figures
List of Figures
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-23
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-18
Figure 3: NAFTA countries ...
List of Figures
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-23
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2014-18
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2018-23
Figure 4: Canada pharmaceuticals market value: $ billion, 2014-18
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 6: Canada pharmaceuticals market share: % share, by value, 2018
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2018-23
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2018
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2018
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2018
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2018
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2018
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2018
Figure 14: Mexico pharmaceuticals market value: $ billion, 2014-18
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2018
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2018-23
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2018
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2018
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2018
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2018
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2018
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2018
Figure 24: United States pharmaceuticals market value: $ billion, 2014-18
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 26: United States pharmaceuticals market share: % share, by value, 2018
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2018-23
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2018
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2018
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2018
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2018
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2018
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2018
Figure 34: Johnson & Johnson: revenues & profitability
Figure 35: Johnson & Johnson: assets & liabilities
Figure 36: Bayer AG: revenues & profitability
Figure 37: Bayer AG: assets & liabilities
Figure 38: Novartis AG: revenues & profitability
Figure 39: Novartis AG: assets & liabilities
Figure 40: AstraZeneca PLC: revenues & profitability
Figure 41: AstraZeneca PLC: assets & liabilities
Figure 42: Merck & Co., Inc.: revenues & profitability
Figure 43: Merck & Co., Inc.: assets & liabilities
Figure 44: Pfizer Inc: revenues & profitability
Figure 45: Pfizer Inc: assets & liabilities